Literature DB >> 22901186

Liver involvement in multiple myeloma: a hospital based retrospective study.

Bibek Poudel1, Ankush Mittal, Rojeet Shrestha, Mohammad Shamim Farooqui, Naval Kishor Yadav, Pramod Shanker Shukla.   

Abstract

OBJECTIVE: This study was to assess liver involvement in multiple myeloma with the aid of liver function tests.
MATERIALS AND METHODS: A hospital based retrospective study was undertaken using data retrieved of multiple myeloma from the register maintained in the Department of Biochemistry of the Manipal Teaching Hospital, Pokhara, Nepal between 1st January, 2007 and 28th February, 2012. We collected biomarkers of liver profiles including bilirubin (Total, Direct and Indirect), total protein, albumin, AG ratio, SGOT, SGPT, ALP, γGT, LDH, ferritin, renal profile and hematological profile. Descriptive statistics and testing of hypothesis were used for the analysis using EPI INFO and SPSS 16 software.
RESULTS: Out of 37 cases of multiple myeloma, serum level of AST, ALT, ALP, γGT and LDH were increased above the cut-off point in 22 (59.5%), 24 (64.86%), 13 (35.13%), 9 (24.3%) and 11 (29.7%) respectively. The mean values of AST (65.5±28.18 U/L), ALT (68.37±29.74 U/L), ALP (328.0±148.4 U/L), γGT (44.5±29.6 U/L) and LDH (361.7±116.5 U/L), total protein (9.79±1.03 gm/ dl) were significantly increased when compared with controls. In contrast, albumin (3.68±0.43 gm/dl) and the AG ratio (0.62±0.15) were significantly decreased. Similarly, anemia, hyperuricemia, azotemia, hypercalcaemia and Bence Jones proteinuria were found in 30 (78.9%), 27 (71.1%), 19 (51.5%), 15 (39.5%) and 16 (42.1%) respectively, in cases of multiple myeloma.
CONCLUSIONS: While clinical manifestation of liver disease among the multiple myeloma was not common, abnormalities in liver function were characteristic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901186     DOI: 10.7314/apjcp.2012.13.5.2153

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.

Authors:  Takayoshi Kiba; Takuo Ito; Toshihisa Nakashima; Yoshiko Okikawa; Miki Kido; Akiko Kimura; Keita Kameda; Fumiaki Miyamae; Suzuko Tanaka; Misao Atsumi; Yoko Sumitani; Yoshimi Shitakubo; Hiromasa Niimi
Journal:  BMC Cancer       Date:  2014-06-21       Impact factor: 4.430

2.  A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas.

Authors:  Yanxia Jin; Yufeng Shang; Hailing Liu; Lu Ding; Xiqin Tong; Honglei Tu; Guolin Yuan; Fuling Zhou
Journal:  Onco Targets Ther       Date:  2019-12-03       Impact factor: 4.147

3.  Obstructive Jaundice as Initial Presentation of Multiple Myeloma: Case Presentation and Literature Review.

Authors:  Yasir Khan; Iyad Mansour; Eric Ong; Manish Shrestha
Journal:  Case Rep Med       Date:  2015-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.